Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/181570
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCasaroli Marano, Ricardo Pedro-
dc.contributor.authorBernal Morales, Carolina-
dc.contributor.authorChamorro López, Lillian-
dc.contributor.authorDotti Boada, Marina-
dc.contributor.authorFigueroa Vercellino, Juan P.-
dc.contributor.authorAlforja, Socorro-
dc.date.accessioned2021-12-01T15:37:43Z-
dc.date.available2021-12-01T15:37:43Z-
dc.date.issued2020-11-21-
dc.identifier.issn2090-004X-
dc.identifier.urihttp://hdl.handle.net/2445/181570-
dc.description.abstractThe current treatment of neovascular age-related macular degeneration (nAMD) generates an excessive care pressure in the public health system. The search for a satisfactory treatment regimen, whose anatomical and functional stability may be achieved, is a challenge and a goal to be reached. We analyzed the outcomes in a patient cohort under fixed regimen treatment with intravitreal aflibercept (IVA). A retrospective study, with at least 1-year follow-up, in consecutive treated unselected naïve patients was carried out. Standard protocol was performed and evaluated at baseline, month 4 (after loading dose, LD), and month 12 (after fixed bimonthly regimen). One hundred six patients (123 eyes) aged 80.3 ± 7.7 years were included, receiving 6.8 ± 0.7 IVA. Visual acuity gain after LD was 5.5 ± 12.0 letters (). At month 12, 23 eyes (18.7%) gained ≥15 letters and 58 (47.1%) had best-corrected visual acuity ≥20/40 (70 letters). The improvement in visual acuity was lower in patients with polypoidal choroidal vasculopathy (+4.9 ± 18.1 letters; p = 0.2544) and somewhat higher in patients with retinal angiomatous proliferation (+5.4 ± 12.3 letters; ). Dry macula was present in only 9.8% of cohort at baseline vs. 69.7% at month 12 (). Atrophy was the most observed complication and related to the elderly patients. The average of follow-up visits was 3 ± 0.5. Functional and anatomical improvement were observed with IVA in a fixed bimonthly regimen treatment after LD, with results maintained up to one year with a good compliance. The fixed bimonthly regimen optimized patient management and logistic issues.-
dc.format.extent8 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherHindawi-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1155/2020/8848336-
dc.relation.ispartofJournal of Ophthalmology, 2020, vol. 2020, num. 8848336-
dc.relation.urihttps://doi.org/10.1155/2020/8848336-
dc.rightscc-by (c) Casaroli Marano, Ricardo Pedro et al., 2020-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subject.classificationTrastorns de la visió-
dc.subject.otherVision disorders-
dc.titleFixed Regimen Treatment in Unselected Naive Patients Cohort with Neovascular Age-Related Macular Degeneration-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec709431-
dc.date.updated2021-12-01T15:37:43Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
Appears in Collections:Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)

Files in This Item:
File Description SizeFormat 
709431.pdf1.29 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons